With DPP-4 inhibitors, 57 events were reported in 45,132 PYOs compared with 46 events in 38,883 PYOs with the comparator treatment
Dr Laura Geige Medical Director and Senior Aesthetics Practitioner at Its Me & You Clinic, with a background in dentistry, medical aesthetics and cosmetic dermatology
Mechanism of action: GLP-1 receptor agonists work through multiple physiological pathways
In a large national cohort study, researchers found that older adults taking GLP-1 receptor agonists had a lower risk of developing both nonneovascular (dry) and neovascular (wet) age-related macular degeneration (AMD) compared with people taking other diabetes or cholesterol-lowering medications
Flying with tirzepatide Air travel introduces unique considerations
GHRP-6 is a hexapeptide that activates the GHS-R1a receptor and stimulates GH release from the pituitary gland